GRAL•prnewswire•
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
Summary
FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 30, 2026 by prnewswire